| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We previously demonstrated that transcutaneous CO2 suppresses the growth of primary human OSCC and metastasis to the regional lymph nodes by both improving hypoxia and increasing mitochondrial apoptosis in treated tissue. Therefore, we hypothesized that improving hypoxia by transcutaneous CO2 could suppress EMT. In the present study, we investigated whether oxygen conditions affect HIF-1α and EMT factors in OSCC in vivo and whether transcutaneous CO2 affects these factors in OSCC. In the present study, in vivo studies revealed that transcutaneous CO2 increased E-cadherin expression with the decreased expression of HIF-1α, Snail, Slug, N-cadherin, and Vimentin in treatment tumors. These results suggest that transcutaneous CO2 could suppress EMT by improving hypoxia, resulting in the reduction of metastatic potential of OSCC. The findings indicate that transcutaneous CO2 may be able to improve the prognosis of OSCC patients through the suppression of EMT.
|
